HC Wainwright Has Positive Estimate for DMAC FY2025 Earnings

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for DiaMedica Therapeutics in a research report issued on Thursday, May 15th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.72) for the year, up from their prior forecast of ($0.73). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for DiaMedica Therapeutics' current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics' FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($0.45) EPS.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.18). During the same period last year, the firm earned ($0.14) earnings per share.

DiaMedica Therapeutics Trading Up 0.2%

Shares of DMAC traded up $0.01 during mid-day trading on Monday, reaching $4.06. The company's stock had a trading volume of 80,803 shares, compared to its average volume of 80,919. DiaMedica Therapeutics has a 1-year low of $2.14 and a 1-year high of $6.82. The stock has a market cap of $174.10 million, a P/E ratio of -7.25 and a beta of 1.29. The business has a 50-day simple moving average of $3.98 and a two-hundred day simple moving average of $4.99.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds have recently made changes to their positions in DMAC. Jane Street Group LLC lifted its holdings in DiaMedica Therapeutics by 138.5% during the 1st quarter. Jane Street Group LLC now owns 100,669 shares of the company's stock worth $382,000 after purchasing an additional 58,457 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in DiaMedica Therapeutics by 76.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company's stock worth $462,000 after purchasing an additional 52,854 shares during the last quarter. Royal Bank of Canada lifted its holdings in DiaMedica Therapeutics by 46,879.1% during the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock worth $588,000 after purchasing an additional 154,701 shares during the last quarter. World Investment Advisors lifted its holdings in DiaMedica Therapeutics by 17.0% during the 1st quarter. World Investment Advisors now owns 25,650 shares of the company's stock worth $97,000 after purchasing an additional 3,735 shares during the last quarter. Finally, Cornerstone Wealth Management LLC acquired a new stake in DiaMedica Therapeutics during the 1st quarter worth approximately $62,000. 10.12% of the stock is owned by institutional investors and hedge funds.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.